Alvotech
- Country
- 🇮🇸Iceland
- Ownership
- Public
- Employees
- 999
- Market Cap
- $3.5B
- Website
- http://www.alvotech.com
- Introduction
Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.
Clinical Trials
0
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
News
Alvotech Restructures Leadership Team with New Commercial Operations Appointments
Alvotech announced significant leadership changes with Chief Commercial Officer Anil Okay stepping down to become CEO of Adalvo, marking a strategic transition in the company's commercial operations.
European Medicines Agency Recommends Approval of Alvotech's Gobivaz Biosimilar to Johnson & Johnson's Simponi
The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval for Gobivaz, Alvotech's proposed biosimilar to Simponi.
Alvotech Secures Japanese Approval for Three Biosimilars Including First Global Golimumab Biosimilar
Alvotech's partner Fuji Pharma received Japanese regulatory approval for three biosimilars: AVT03 (denosumab), AVT05 (golimumab), and AVT06 (aflibercept) from the Ministry of Health, Labor and Welfare.
Alvotech Reports Record First Half 2025 Results with Over 200% Product Revenue Growth
Alvotech achieved over 200% year-on-year growth in product revenues for the first six months of 2025, reaching $204.7 million compared to $65.9 million in the same period of 2024.
Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer
Alvotech, a global biosimilar medicines company, has appointed Linda Jónsdóttir as Chief Financial Officer, bringing 15 years of senior leadership experience from Marel food processing technology company.
Alvotech Acquires Swiss Packaging Specialist Ivers-Lee to Expand Biosimilar Manufacturing Capacity
Alvotech has acquired Ivers-Lee Group, a Swiss family-owned pharmaceutical packaging company founded in 1947, to expand its assembly and packaging capabilities ahead of three new biosimilar launches in 2025.
EMA Recommends Approval of Alvotech's Biosimilar to Eylea for Eye Disorders
The European Medicines Agency's Committee for Medicinal Products for Human Use adopted a positive opinion recommending approval for AVT06, Alvotech's proposed biosimilar to Eylea (aflibercept 2 mg).
Major PBMs Exclude Humira Biosimilars from 2025 Formularies, Favor Private-Label Products
The three largest U.S. pharmacy benefit managers have excluded nearly all marketed Humira biosimilars from their 2025 standard formularies, marking a dramatic shift from 2024 when eight products were covered.
Dr. Reddy's and Alvotech Partner to Develop Keytruda Biosimilar in $29.5 Billion Market
Dr. Reddy's Laboratories and Alvotech have entered a collaboration and license agreement to co-develop, manufacture, and commercialize a biosimilar version of Keytruda (pembrolizumab) for global markets.
Alvotech and Advanz Pharma Expand $13.8 Billion Biosimilar Partnership with Three New Candidates
Alvotech and Advanz Pharma have expanded their strategic partnership to include three additional biosimilar candidates, bringing their total European portfolio to more than ten reference products.